| Gene symbol | TNFSF4 | Synonyms | CD134L, CD252, GP34, OX-40L, OX4OL, TNLG2B, TXGP1 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q25.1 | dbXrefs | |
| Description | TNF superfamily member 4 | ||||
| GTO ID | GTC1807 |
| Trial ID | NCT03323398 |
| Disease | Lymphoma | Ovarian Cancer |
| Altered gene | TNFSF4 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-2416 |
| Phase | Phase1|Phase2 |
| Recruitment status | Terminated |
| Title | A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies |
| Year | 2017 |
| Country | Belgium|Bulgaria|Canada|France|Germany|Israel|Italy|Netherlands|Poland|Puerto Rico|Spain|Turkey|United Kingdom|United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-2416-P101 |
| Vector information | |||
|
|||
| Cohort1: mRNA-2416 | |||||||
|
|||||||
| Cohort2: mRNA-2416_Durvalumab | |||||||
|
|||||||